We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Silica-Based Nanoparticles Selectively Kill Lung Cancer Cells

By LabMedica International staff writers
Posted on 16 Mar 2015
Print article
Image: TEM (transmission electron micrograph) of a mesoporous silica nanoparticle (Photo courtesy of Wikimedia Commons).
Image: TEM (transmission electron micrograph) of a mesoporous silica nanoparticle (Photo courtesy of Wikimedia Commons).
A novel approach to the selective delivery of toxic chemotherapeutic agents is based on nanoparticles that sequester the drug until it is liberated by the action of specific proteases that are present in a high concentration inside lung cancer cells.

Investigators at the German Research Center for Environmental Health (Munich, Germany) constructed the nanoparticles—basically extremely small open-ended boxes—from mesoporous silica (containing pores with diameters between two and 50 nanometers) tightly capped at each end by avidin molecules linked by proteins sensitive to the action of the protease MMP9 (matrix metalloproteinase 9). The nanoparticles were loaded with the cancer drug cisplatin, which was safely sequestered as long as the avidin-protein caps remained intact.

The justification for use of these nanoparticles was the fact that the protease MMP9 was overexpressed in tumors. It was known to enhance the metastatic potency of malignant cells and had been associated with poor prognosis of lung cancer.

The investigators studied the impact of cisplatin-containing nanoparticles on mouse tumors in vivo and on mouse and human lung tumors being grown in novel ex vivo three-dimensional lung tissue cultures.

They reported in the February 22, 2015, online edition of the journal ACS Nano that the MMP9-mediated release of cisplatin induced apoptotic cell death only in lung tumor regions of Kras mutant mice without causing toxicity in tumor-free areas or in healthy mice. The MMP9-responsive nanoparticles also allowed for effective combinatorial drug delivery of cisplatin and the proteasome inhibitor bortezomib, which had a synergistic effect on the therapeutic efficiency. The concentration of MMP9 in healthy lung tissue was too low to destroy the nanoparticles' protective layer and the drugs remained sequestered inside the nanocarriers.

"Using these nanocarriers we can very selectively release a drug such as a chemotherapeutic agent specifically at the lung tumor," said senior author Dr. Silke Meiners, a group leader at the German Research Center for Environmental Health. "We observed that the drug's effectiveness in the tumor tissue was 10 to 25 times greater compared to when the drugs were used on their own. At the same time, this approach also makes it possible to decrease the total dose of medicines and consequently to reduce undesirable effects."

Related Links:

German Research Center for Environmental Health


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.